Cyproterone acetate
As of the edition of 20 October 2026, Cyproterone acetate is a small molecule: marketed, first approved in 1974 (ES); acts on AR and PGR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1987
- Kind
- Small molecule
- Brand name
- Androcur
- First approved
- 1 November 1974 (ES)
- Approvals on record
- 3 in 2 regions
- Holder of the most recent approval
- Bayer; 3 holders in all
- Registered trials
- 21, 1 stopped early
- Disease areas
- Cancer; Urinary and reproductive; Hormones; Pregnancy and women's health; Mental health; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company-target row on route B because of this drug.
Companies on route B for this drug
In the product1 company-target row is on route B because of Cyproterone acetate.
See the 1 company-target row on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 10 | 8 | 1 | 1 |
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 5 | 3 | 1 | 0 |
| Phase 4 | 5 | 3 | 0 | 0 |
| All trials | 21 |